This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Imagine being able to create an in vitro replica of a diseased organ to study the molecular mechanism underlying the illness. Now take a step further: envision testing drugs in these organoids to identify the ones that can treat disease safely and effectively without needing to run expensive clinical trials first.
But as molecularbiology has advanced, so too has our approach to finding new drugs. Today, we're able to identify and target specific molecules involved in disease processes—a method that's much more like using a sniper rifle than throwing darts blindfolded. This method was more about serendipity than science.
How does precision neuroscience differ from traditional approaches in the treatment of neurodegenerative diseases, and what advantages does it offer? Traditionally, Alzheimer’s disease is diagnosed by clinical examination, medical history and cognitive testing. We believe we are at a breakthrough moment in Alzheimer’s disease research.
Sibylla’s scientific founders come from very different scientific fields that do not usually speak to each other, such as theoretical physics, molecularbiology and pharmaceutical chemistry. Our ongoing research and development are poised to explore these avenues, aiming to address complex diseases with novel therapeutics.
Internships at Altasciences: Q&A With Our Summer Interns nbartlett Thu, 08/22/2024 - 04:44 Internships at Altasciences are more than just a stepping stone—they’re a gateway to real-world-experience and professional growth, giving the next generation opportunities to help shape progress in the drug development industry. The work environment.
He started to imagine how the deadly and contagious disease, if confirmed, might spread to half the city’s population. Eight of the 20 patients died, but the spread of the disease in Nigeria stopped there. Blood and urine samples from the man were waiting for Happi in his lab. Happi felt chilled. They called the idea Sentinel.
The funds will be used to advance its nose-on-chip platform to detect the characteristic smell linked to Parkinson’s disease (PD). Yesse Technologies scientists recently validated the presence of a distinctive smell, arising from an oily skin secretion called sebum, in patients diagnosed with Parkinson’s disease.
“The establishment of an Advisory Board focusing on Alzheimer’s disease, and the recruitment of such an impressive group of scientific and clinical leaders in this field is an extremely important step forward for the Company,” stated Paul Brennan, NervGen’s President & CEO.
Dr.
Born in 1970, the British and American research scientist has been Director of the Department of Microbiome Research at the Max Planck Institute for Developmental Biology in Tübingen since 2016. Before, she was associate professor at Cornell University in the Department of MolecularBiology and Genetics.
Her research focus is on epigenetic regulation of melanoma and other cancers as well as wound healing, ageing biology and the development of novel epigenetic therapies targeting cancers and skin diseases and she is the owner of 15 issued and pending patents relevant to her research. Dr Alani received her M.D.
Program has advanced rapidly under an international collaboration of companies led by Sosei Heptares as part of its commitment to socially responsible investing.
Mark Swallow , David Dible – International Media
+44 (0)20 7638 9571 | SoseiHeptares@citigatedewerogerson.com.
TOKYO and CAMBRIDGE, England , Nov.
I can only hope that their STS experience further inspires them to take on and help solve the biggest challenges facing mankind – from climate change to disease and future pandemics.” About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.
A BBC documentary on ‘The Virus that Cures’ was broadcast around the world in 1997, and in the former communist party headquarters in Georgia, American investors helped organize the first major international conference on phage therapy since the 1930s. alone, according to the Centers for Disease Control and Prevention.
Currently, this portfolio includes molecular, serology and digital solutions which help diagnose and manage COVID-19 during the initial stages of infection, during the recovery phase, as well as following the resolution of infection. The molecularbiology of coronaviruses. The Lancet 396:479 – 4882) [2] Masters PS (2006).
Klebahn placed the algae cells into an enclosed chamber beneath his light microscope, and then pumped in air until its internal pressure rose to twice, then three-times, normal atmospheric levels. By measuring the length of time that it takes for a soundwave to enter and return, an ultrasound device constructs an internal image of the body.
CNGA3-achromatopsia is a hereditary disease that causes people to see in shades of gray. in Current Biology. They’re talking about a patient who has a rare genetic disease. ” Wellcome Collection , London I wrapped up my series on “30 Days of Great Biology Papers.” From Sulis D.B. in Science.
CNGA3-achromatopsia is a hereditary disease that causes people to see in shades of gray. in Current Biology. They’re talking about a patient who has a rare genetic disease. ” Wellcome Collection , London I wrapped up my series on “30 Days of Great Biology Papers.” From Sulis D.B. in Science.
I recently asked for recommendations of “classic” papers in molecularbiology. And a Phase I study for three patients with late-onset Pompe disease, a rare genetic disorder that causes glycogen to build up inside of cells and causes the heart and skeletal muscles to slowly break down, also looks promising.
The animals had a common disease variant, caused by a single amino acid substitution in the phenylalanine hydroxylase enzyme. Future Nobel Laureate, Paul Berg, narrated the video, which quickly became a cult classic moment in molecularbiology history. “Of course, many already have the ability to do harm with biology.
The animals had a common disease variant, caused by a single amino acid substitution in the phenylalanine hydroxylase enzyme. Future Nobel Laureate, Paul Berg, narrated the video, which quickly became a cult classic moment in molecularbiology history. “Of course, many already have the ability to do harm with biology.
Rising demand for animal protein has led to more factory farming, increasing the likelihood that diseases can spread among these animals then into humans. 5 Furthermore, ever larger numbers of humans are living in cities or travelling across borders, increasing the risk of diseases being transmitted person-to-person over a long range.
These versatile cells can be reprogrammed to become virtually any cell type in the human body, offering groundbreaking possibilities for treating a wide range of conditions, from genetic disorders to degenerative diseases. Cedrone holds a PhD in molecularbiology and enzyme engineering from Marseille University, France.
That is a small number relative to other infectious diseases, but one of the reasons a strep A vaccine is intriguing is because making one will be incredibly difficult; there are more than 200 types of bacteria that cause strep A, each carrying unique M proteins on their cell walls. We want to commission an essay that celebrates sewage.
A clinical genomicist harnesses team-based science to help rare-disease patients By Allessandra DiCorato January 7, 2025 Breadcrumb Home A clinical genomicist harnesses team-based science to help rare-disease patients Heidi Rehm convinced labs and scientists to work together and share data.
The same team also invented several other products that proved useful for treating battlefield injuries, including gamma globulins to inoculate soldiers against diseases and fibrin film to minimize bleeding during brain surgeries. Still, Cohn’s work ought to be iconic amongst those interested in scientific progress and metascience.
declared war on COVID and sacrificed large swathes of its economy to prevent the spread of this dreaded disease. professor of international health at the Bloomberg School of Public Health, Johns Hopkins University, told BioSpace. The pharmaceutical industry has battled COVID-19 since the moment members learned of it.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content